MARKET

LGNZZ

LGNZZ

Ligand Pharma
OTCPK
0.070
NaN%
Closed 09:30 04/02 EDT
OPEN
--
PREV CLOSE
0.070
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.140
52 WEEK LOW
0.070
MARKET CAP
--
P/E (TTM)
0.011
1D
5D
1M
3M
1Y
5Y
1D
Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Seeking Alpha · 02/26 22:48
Benchmark Maintains Ligand Pharmaceuticals Incorporated - Equity Right (LGNZZ) Buy Recommendation
NASDAQ · 11/08/2025 03:42
HC Wainwright & Co. Maintains Ligand Pharmaceuticals Incorporated - Equity Right (LGNZZ) Buy Recommendation
NASDAQ · 11/07/2025 03:33
Weekly Report: what happened at LGNZZ last week (0908-0912)?
Weekly Report · 09/15/2025 10:10
Weekly Report: what happened at LGNZZ last week (0901-0905)?
Weekly Report · 09/08/2025 10:11
Weekly Report: what happened at LGNZZ last week (0825-0829)?
Weekly Report · 09/01/2025 10:09
Weekly Report: what happened at LGNZZ last week (0818-0822)?
Weekly Report · 08/25/2025 10:14
Weekly Report: what happened at LGNZZ last week (0811-0815)?
Weekly Report · 08/18/2025 10:10
More
About LGNZZ
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Webull offers Ligand Pharmaceuticals Inc stock information, including OTCPK: LGNZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGNZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGNZZ stock methods without spending real money on the virtual paper trading platform.